CD40 Ligand antibody (C-Term)

Catalog No. ABIN652211

The Rabbit Polyclonal anti-CD40 Ligand antibody is suitable to detect CD40 Ligand in samples from Human. It has been validated for WB, FACS and IHC (p).

Quick Overview for CD40 Ligand antibody (C-Term) (ABIN652211)

Target: CD40 Ligand (CD40LG)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD40 Ligand antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB19151

Product Details anti-CD40 Ligand Antibody

Binding Specificity: AA 181-207, C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This TRAP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-207 amino acids from the C-terminal region of human TRAP.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:50~100. FC: 1:10~50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: TRAP

Background: TRAP is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in its gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome.

Molecular Weight: 29274

Gene ID: 959

NCBI Accession: NP_000065

UniProt: P29965

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints